04/20/2022 / By Arsenio Toledo
A European medical and biotechnology company is attempting to control people’s brains by developing medical devices that use a medical procedure known as neuromodulation.
This is according to Dr. Steve Hotze and the Health Ranger Mike Adams, who discussed neuromodulation and nanotechnology during the April 18 episode of “The Dr. Hotze Report” on Brighteon.TV.
Neuromodulation refers to the alteration of nerve activity in the body through the targeted delivery of certain stimuli to the nerves. This can be done through electrical stimulation or through the use of chemical agents.
One company that has become notable for its developments in the field of neuromodulation is INBRAIN Neuroelectronics, a company based in Spain that is a spin-off of the Graphene Flagship, a scientific research initiative of the European Union that conducts experiments on the applications of graphene.
According to Adams, INBRAIN is primarily focused on developing neuromodulation devices for their medical applications.
The technology could be used to monitor brain impulses for signs of neurological disorders such as epilepsy, Alzheimer’s and dementia. Theoretically, neuromodulation could be used to send impulses to the brain “in order to try to override epilepsy or override Alzheimer’s, and so on,” said Adams.
INBRAIN has received millions of dollars in venture capital funding from investors interested in their research and in the practical applications of neuromodulation.
“It’s not science fiction, it’s absolute reality,” said Adams. “But, you must understand, they’re both reading your brain and then they’re controlling your brain. Now, they may start with a medical application, but think about where these technologies go from there.”
“Often, this tech can be abused in order to control people or to even punish people for thinking the wrong thoughts by firing off, you know, punishment impulses inside their brain, if they are not going along with the official narrative,” continued Adams.
Hotze and Adams noted that the substance INBRAIN plans to use to get its medical devices to interact and interface with the brain is graphene oxide, a toxic substance that has been found in Wuhan coronavirus (COVID-19) vaccines and is known to be spread by vaccinated individuals from person to person, causing debilitating health conditions. (Related: Researcher sounds alarm after finding PARASITES, nanobots and graphene in COVID-19 vaccines.)
INBRAIN itself has admitted that it plans to create graphene-based neural implants, supposedly to provide people with “personalized therapeutic options for brain disorders.”
The company claims its graphene implants are designed to accurately interpret the signals the brain sends out and it then provides the wearer of the implant with a therapeutic response adapted to their specific neurological condition.
Hotze warned that these graphene implants could eventually be used “to identify who you are, where you are and what your thoughts are.”
He further warned that Big Tech companies could essentially piggyback off this technology to advance their transhumanist agenda. Hotze noted that Google Director of Engineering Ray Kurzweil himself believes that technology like this could be used to turn virtually all human thinking non-biological by 2040.
“That means we’re gonna be artificial intelligence, we’re going to be controlled by outside forces,” said Hotze. “Now, that is chilling indeed.”
Read more stories like this at MindControl.news.
Watch the full April 18 episode of “The Dr. Hotze Report” below. “The Dr. Hotze Report” airs every Monday and Saturday from 5-6 p.m. on Brighteon.TV.
Pfizer’s COVID-19 vaccines contain nanotechnology to track people, scientists say.
Sources include:
Tagged Under:
biotechnology, brain function, evil, future science, future tech, graphene, Health Ranger, inventions, medical tech, Mike Adams, mind control, nanotechnology, neuromodulation, slavery, Steve Hotze, The Dr. Hotze Report, transhumanism
This article may contain statements that reflect the opinion of the author
COPYRIGHT © 2017 BIO TECH NEWS